Product name
Ecto-NTPDase-Inhibitors as highly selective indirect agonists of P2-receptors from University BonnSummary
Regulation of P2 receptor subtypes e.g. in mucoviscidosis and cancerOrganization name
Provendis GmbHProfile
The invention provides a new class of nucleosides exhibiting a high affinity for individual ecto-nucleotidetriphosphate-diphosphohydrolases (E-NTPDase s) which have been developed by researchers at the University of Bonn. The inhibitors are capable of inhibiting the metabolization of nucleotides by individual E-NTPDases and thus act as a highly selective indirect agonists of P2-receptors (ATP-, ADP-, UTP-, UDP-receptors).
Therapeutic compounds which facilitate the signal transduction via P2-receptors can be used e.g. for the treatment of mucoviscidosis and cancer or for the modulation of inflammatory processes and the immune system. Furthermore, such compounds are valuable tools in biopharmaceutical research. The present invention thus comprises a novel class of therapeutically active compounds as well as methods for preparing the same.
current status
The inhibitory effect of the compounds has been demonstrated in a tailored assay based on capillary electrophoresis developed at the University of Bonn. The selectivity of the compounds according to the invention with respect to different P2Y-receptor-subtypes has been shown convincingly. Data from comparable studies using standard compounds such as Reactive Blue 2, PPADS, Suramin and ARL67156 are available.
Contact
Dr. Andreas Wagener
Tel: +49 208 94 105 38
aw(at)provendis.info
About PROvendis GmbH
PROvendis offers companies certified and patented innovations from 24 North Rhine-Westphalian universities. The core function of the enterprise is to market patentable and commercially exploitable inventions. PROvendis GmbH was founded in 2001 as a wholly owned subsidiary of Zenit GmbH, a management consultancy firm in cooperation with the state of North Rhine-Westphalia. Since January of 2002, PROvendis has been the service provider for the universities of the state of North Rhine-Westphalia. Within the scope of the BMBF commercialization campaign, the Federal Ministry for Education and Research (BMBF) supports the activities of PROvendis.
Description File
1115EctonucleotidaseInhibitor_EN.pdf
print this page
